Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held at the Nasdaq ...

Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...

Nektar Therapeutics’ hopes of rebuilding its battered business around lupus lie in tatters. The key phase 2 clinical trial of rezpegaldesleukin missed its primary endpoint, prompting partner Eli ...

Nektar stock pops as more than half of San Francisco office loses jobs, new CFO appointed Last Updated: April 17, 2023 at 6:03 p.m. ET First Published: April 17, 2023 at 5:54 p.m. ET Share ...

Nektar's stock was up 3 cents in after-hours trading Monday to $1.01. It's 52-week price has ranged from 60 cents to $5.18 per share, but it opened last year at $13.58.

In a recent filing with the Securities and Exchange Commission, Nektar Therapeutics (NASDAQ:NKTR) disclosed a significant change in its senior leadership team. The announcement comes as the ...

Nektar confirmed the news in a separate release, announcing plans to push forward with rezpeg in atopic dermatitis. Rezpeb failed to meet expectations in a phase 2 lupus study back in February.

Nektar’s drug, bempegaldesleukin (bempeg) is an engineered cytokine, a signalling protein that prompts an immune response. Bempeg is Nektar’s version of a cytokine called interleukin-2 (IL-2).